| 12.10.24 | BioNTech bispecific shows potential to usurp Keytruda; GSK starts $45M Relation-ship with AI biotech

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

6 Monate vor

Html
Text

Complying with FDA’s Corrections and Removals Process: A Guide for LDTs

Stage 1 of the FDA’s LDT phaseout policy is fast approaching and will require strict adherence to the corrections and removals process. Remain compliant and safeguard public health – download our guide for the 7-step overview.

Today’s Big News

Dec 10, 2024

BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer

Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup

GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets

NewAmsterdam's stock rises on early sign cholesterol drug improves cardiovascular outcomes

CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial

Relmada turns to strategic options after scrapping 2 phase 3 trials

Fierce Biotech Fundraising Tracker '24: Tasca takes off with $52M; Citryll circles up $89M

Belharra's tide falls as the chemoproteomics biotech lays off 21 workers


A message from Perceptive

Featured

BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer

By Nick Paul Taylor

BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial benchmark and supporting use in a broader population.

Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup

By James Waldron

Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the blood cancer drug “did not reach Lava’s internal benchmarks.”

GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets

By James Waldron

GSK has handed over $45 million upfront to fellow London, U.K.-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis.

What’s next in AI’s drug discovery journey

NewAmsterdam's stock rises on early sign cholesterol drug improves cardiovascular outcomes

By Nick Paul Taylor

NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting candidate. And, having struggled to wow investors with earlier data, the biotech sweetened its latest pitch with early suggestions that the molecule improves cardiovascular outcomes.

CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial

By James Waldron

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study.

Relmada turns to strategic options after scrapping 2 phase 3 trials

By Darren Incorvaia

After a data monitoring committee found that the RELIANCE II study of REL-1017 is unlikely to hit its primary endpoint, Relmada Therapeutics is scrapping both the RELIANCE II and Relight phase 3 trials of REL-1017 in major depressive disorder, the company announced on Dec. 9.

Fierce Biotech Fundraising Tracker '24: Tasca takes off with $52M; Citryll circles up $89M

By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer

Welcome to Fierce Biotech's Fundraising Tracker, 2024's version.

Belharra's tide falls as the chemoproteomics biotech lays off 21 workers

By Gabrielle Masson

The layoffs will allow Belharra to extend its cash runway “to achieve key inflection points while alleviating capital raise pressures, particularly given the persistent uncertainties and fluctuations of the funding environment,” a spokesperson told Fierce Biotech.

NYPD: A 'strong person of interest' in UnitedHealthcare CEO's death arrested in Pennsylvania

By Paige Minemyer

The New York Police Department confirmed that there is a man in custody in central Pennsylvania in connection with the shooting death of UnitedHealthcare CEO Brian Thompson.

High-flying Eli Lilly plots $15B share buyback plan

By Zoey Becker

The share buyback program comes after a recent $5 billion buyback campaign the company completed during the current quarter.

Fierce podcasts

Don’t miss an episode

What can we learn from 2024’s biotech IPOs?

This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay?

NCQA: Best practices for measuring health inequities

Meet 2024’s fiercest women in life sciences


A message from Promab Biotechnologies

Resources

Whitepaper

Building a “Best Practice” R&D Organization in Biopharma

We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

Whitepaper

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific